文献速递脑血管病

TIA或缺血性卒中后抗血小板治疗早期大出血的时间进程

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke.
PubMed 文献 · Neurology · 2018-01-26

该研究基于6项随机临床试验的45,195例TIA或非心源性缺血性卒中患者个体数据,分析双联与单联抗血小板治疗下大出血的早期时间进程。结果显示,阿司匹林联合氯吡格雷及阿司匹林联合双嘧达莫的大出血发生率在最初30天最高,分别为5.8和4.9/100人年,显著高于31-90天;单药治疗则无显著时间变化。双联抗血小板治疗与早期大出血及胃肠道出血高风险相关,首月后风险下降。

要点

  • 双联抗血小板治疗的大出血风险在首月最高,随后下降。
  • 阿司匹林联合氯吡格雷首30天大出血发生率为5.8/100人年。
  • 单联抗血小板治疗的大出血发生率无显著时间变化。

核心结论

  • 双联抗血小板治疗与早期大出血和胃肠道出血高风险相关,首月后风险下降。

研究设计与样本

  • 对6项随机临床试验(CAPRIE、ESPS-2、MATCH、CHARISMA、ESPRIT、PRoFESS)的个体患者数据进行事后分析,共纳入45,195例TIA或非心源性缺血性卒中患者。

主要发现

  • 阿司匹林联合氯吡格雷和阿司匹林联合双嘧达莫的大出血发生率在最初30天最高,分别为5.8和4.9/100人年。
  • 阿司匹林联合氯吡格雷在31-90天的大出血发生率显著低于最初30天,率比为1.98(95%CI 1.16-3.40)。
  • 阿司匹林联合双嘧达莫在31-90天的大出血发生率显著低于最初30天,率比为1.94(95%CI 1.24-3.03)。
  • 阿司匹林和氯吡格雷单药治疗在最初30天的大出血发生率分别为2.8和2.5/100人年,随时间无显著变化。
  • 胃肠道出血的时间进程与总体大出血相似;双联或单联抗血小板治疗均未观察到早期颅内出血超额风险。

临床怎么用

  • 对TIA或缺血性卒中后接受双联抗血小板治疗的患者,应警惕首月内大出血和胃肠道出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the early time course of major bleeding and its subtypes in patients with cerebral ischemia on dual and single antiplatelet therapy. METHODS: We performed a post hoc analysis on individual patient data from 6 randomized clinical trials (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second European Stroke Prevention Study [ESPS-2], Management of Atherothrombosis With Clopidogrel in High-Risk Patients [MATCH], Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA], European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT], and Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]) including 45,195 patients with a TIA or noncardioembolic ischemic stroke. We studied incidence rates of bleeding per antiplatelet regimen stratified by time from randomization (≤30, 31-90, 91-180, 181-365, >365 days). We calculated incidence rates per trial and pooled estimates with random-effects meta-analysis. We performed Poisson regression to assess differences between time periods with adjustment for age and sex. RESULTS: The incidence of major bleeding on aspirin plus clopidogrel and aspirin plus -dipyridamole was highest in the first 30 days, 5.8 and 4.9 per 100 person-years, respectively, and was significantly higher than at 31 to 90 days (rate ratio 1.98, 95% confidence interval 1.16-3.40 for aspirin plus clopidogrel; rate ratio 1.94, 95% confidence interval 1.24-3.03 for aspirin plus dipyridamole). Incidence rates on aspirin and clopidogrel monotherapy were 2.8 and 2.5 per 100 person-years, respectively, in the first 30 days, with no significant change over time. The time course was similar for gastrointestinal bleeds. There was no early excess of intracranial hemorrhage in patients on either dual or single antiplatelet therapy. CONCLUSION: Dual antiplatelet therapy is associated with high early risks of major and gastrointestinal bleeding that decline after the first month in trial cohorts.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hilkens NA, Algra A, Kappelle LJ, et al. Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke. Neurology. 2018. PMID: 29374102. doi:10.1212/WNL.0000000000004997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。